Antiviral therapy for cryoglobulinemic neuropathy: comment on the article by Saadoun et al.
Franco
F
Gemignani
Francesca
F
Brindani
Adriana
A
Marbini
D000998:Antiviral Agents / Q000627:therapeutic use*; D003449:Cryoglobulinemia / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D004337:Drug Carriers; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012074:Remission Induction; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b